Cancer
Researchers in the United Kingdom are developing trastuzumab emtansine, an antibody-drug conjugate, for the treatment of HER2+ metastatic breast cancer. Studies have shown that trastuzumab emtansine is effective in breast cancer cell lines resistant to trastuzumab and demonstrated complete tumor regression in SCID mice bearing KPL4 breast cancer xenografts. Clinical
Cancer research
Scientists in Kurume, Japan, have investigated the therapeutic potential of the combination of the proteasome inhibitor bortezomib and the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) on human esophageal squamous cell carcinoma (ESCC) cell lines. The study found that bortezomib enhanced the susceptibility of ESCC cells to TRAIL-induced apoptosis, and
Cancer research
A groundbreaking study has been published, offering new insights into the use of recombinant human Apo2L/TRAIL as a potential cancer therapy. The phase I dose-escalation study, conducted by researchers at the University of Texas M. D. Anderson Cancer Center, assessed the safety, tolerability, pharmacokinetics, and antitumor activity of multiple
Cancer research
Recent research from the United States has unveiled a novel mechanism for enhancing the efficacy of radiation therapy in cancer treatment. A study published in Oncogene by K.W. Kim and colleagues at Vanderbilt University found that endoplasmic reticulum stress plays a crucial role in mediating radiation-induced autophagy in caspase-3/
Cancer research
A recent report published in Molecular Pharmaceutics has shed light on a new approach to treating ovarian cancer using nitric oxide-releasing silica nanoparticles. The study, conducted by E.V. Stevens and colleagues at the University of North Carolina, Lineberger Comprehensive Cancer Center, demonstrates the potential of these nanoparticles in selectively
Scientists
Recent research published in the Oncology Reports journal reveals that zoledronic acid, a third-generation bisphosphonate, has direct anti-tumor effects and can synergistically augment the effects of antitumor agents in human fibrosarcoma cells. The study, conducted by K. Koto and colleagues from the Kyoto Prefectural University, Department of Orthopaedics, found that
Scientists
Researchers at the University of Texas M.D. Anderson Cancer Center have identified the key mechanism through which glioma cells migrate, with the insulin-like growth factor binding protein 2 (IGFBP2) and integrin alpha5 interaction playing a crucial role. This interaction, which enhances cell migration, was found to be mediated by
Cancer research
Researchers at the Medical University of Vienna in Austria have made a significant discovery in the field of cancer therapy, detailing the intracellular protein binding patterns of two ruthenium-based anticancer drugs, KP1019 and KP1339. The study, published in the Journal of Biological Inorganic Chemistry, aimed to evaluate the intracellular uptake
Cancer research
Research published in the Journal of Experimental & Clinical Cancer Research has demonstrated the effectiveness of dendritic cell (DC) vaccines expressing melanoma antigen gene-1 (MAGE-1) in inducing anti-tumor immunity against gastric cancer. The study, conducted by researchers at the First Affiliated Hospital of Soochow University in Suzhou, People's
Cancer research
In a newly published study in Pediatric Blood & Cancer, researchers from the United States reported promising results for treating stage 4a metastatic retinoblastoma patients with intensive conventional chemotherapy, high-dose chemotherapy with autologous hematopoietic stem cell rescue, and radiation therapy. The study presented an expanded and updated series of 15
Cancer research
Scientists in Stockholm, Sweden, have published a report examining the short-term and medium-term risks of cancer in patients receiving anti-tumor necrosis factor alpha (anti-TNF-alpha) therapies for chronic inflammatory conditions. The study, which linked data from the Swedish Biologics Register, Swedish registers of RA, and the Swedish Cancer Register, identified a
Scientists
In a promising development, researchers in the United States have reported a successful treatment of stage 4B retinoblastoma, a highly aggressive form of eye cancer, using high-dose chemotherapy with autologous hematopoietic stem cell rescue. The study, published in Pediatric Blood & Cancer, involved eight patients with stage 4B retinoblastoma who
